Formulation Featured Articles

1. Expanding The IV → SC Framework: What Reformulation Really Means 4/22/2026

   IV → SC is a system design challenge. Success depends on aligning formulation, device, manufacturing, and clinical strategy early to avoid costly failures and redesigns.

2. How To Select The Right Platform For Your Vaccine Production Process 4/16/2026

   Evaluate surface treatments, scalability, and contamination risks to select the right adherent platform. Testing early ensures a seamless transition from benchtop to production.

3. Drug-Device Combination Products: 4 Evolving Platforms For 2026 4/10/2026

   Biologic advantage won’t come from better biology alone, but from delivery technology and designing the full experience around patients, providers, and supply chains.

4. Integrate Upstream/Downstream To Reduce Development Risks And Costs 4/8/2026

   Coordinating unit operations can help reduce costs and mitigate challenges in process development. Check out these key takeaways from the Bioprocess Online Live event “Optimizing Process Development Through Upstream and Downstream Integration.”

5. From IV To Subcutaneous: It's Not About Convenience, It's About System Design 4/6/2026

   IV→SC transition extends beyond dose, volume, concentration, and device; it requires integrated system design, not a series of isolated optimizations.

6. Evaluating Mass Spectrometry Methods For Host Cell Protein Quantification 3/26/2026

   New USP 1132.1 guidelines standardize mass spectrometry for host cell protein analysis. These methods provide the specific protein identification and quantification needed to reduce clinical risk.

7. How Predictive Algorithms Will Redefine Cell Culture Media Development 3/25/2026

   Discover how predictive modeling and AI are reshaping cell culture media development in biopharmaceutical manufacturing — accelerating timelines and enabling smarter, data-driven formulation strategies.

8. How Drugs Are Manufactured And Administered 3/16/2026

   Modern medicine includes far more than familiar over‑the‑counter products. Explore how drug composition, formulation, and administration work together to shape today’s therapies.

9. Scaling MSC Therapies: Overcoming Cell Therapy Manufacturing Risks And Barriers 2/26/2026

   Achieve scalable MSC manufacturing by implementing closed systems and modular scale-out strategies that minimize contamination risks and ensure consistent cellular stability and efficacy.

10. Clearing The Path To Approval: Residual Reagent Control In AAV Gene Therapy 2/22/2026

    Stricter regulatory expectations for AAV therapies demand robust control of residual transfection reagents, comprehensive documentation, and proactive quality strategies to avoid costly development delays.